CD274 and neoplasm: Ad5-CMV-mTNFα/mIL-2 monotherapy provided better response compared to both mAb monotherapies as observed by better tumor growth control and median overall survival (anti-PD1 [42 day], anti-PD-L1 [50 days] and Ad5-CMV-mTNFα/mIL-2 [58 days].